Cipla is currently trading at Rs. 439.25, up by 25.70 points or 6.21% from its previous closing of Rs. 413.55 on the BSE.The scrip opened at Rs. 425.00 and has touched a high and low of Rs. 442.50 and Rs. 417.10 respectively. So far 118869 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 356.75 on 13-Mar-2020.Last one week high and low of the scrip stood at Rs. 447.85 and Rs. 391.35 respectively. The current market cap of the company is Rs. 35059.14 crore.The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.Cipla has successful completed Phase-3 clinical end-point study for fluticasone propionate and salmeterol inhalation powder (100/50 mcg). Fluticasone propionate and salmeterol inhalation powder 100/50 mcg, 250/50 mcg and 500/50 mcg are generic versions of GSK’s Advair Diskus. The product is indicated to treat asthma in patients 4 years and older as a twice-daily prescription medicine and in long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups. The Phase-3 study, successfully completed in the first attempt, was conducted over a period of 15 months at over 100 sites in the US enrolling 1400 asthma patients.Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is currently trading at Rs. 404.20, up by 17.55 points or 4.54% from its previous closing of Rs. 386.65 on the BSE.The scrip opened at Rs. 397.70 and has touched a high and low of Rs. 408.80 and Rs. 391.35 respectively. So far 177918 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 356.75 on 13-Mar-2020.Last one week high and low of the scrip stood at Rs. 432.00 and Rs. 371.65 respectively. The current market cap of the company is Rs. 32539.66 crore.The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Esomeprazole for Oral Suspension 10mg, 20mg and 40mg from the United States Food and Drug Administration (US FDA). Cipla is the first company to file for the 10mg strength.The company’s Esomeprazole for Oral Suspension 10mg, 20mg and 40mg is AB-rated generic therapeutic equivalent version of AstraZeneca Pharmaceutical’s Nexium.Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is currently trading at Rs. 388.95, up by 12.25 points or 3.25% from its previous closing of Rs. 376.70 on the BSE.The scrip opened at Rs. 384.50 and has touched a high and low of Rs. 393.00 and Rs. 381.10 respectively. So far 75632 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 356.75 on 13-Mar-2020.Last one week high and low of the scrip stood at Rs. 432.00 and Rs. 371.65 respectively. The current market cap of the company is Rs. 31237.59 crore.The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Esomeprazole for Oral Suspension 10mg, 20mg and 40mg from the United States Food and Drug Administration (US FDA). Cipla is the first company to file for the 10mg strength.The company’s Esomeprazole for Oral Suspension 10mg, 20mg and 40mg is AB-rated generic therapeutic equivalent version of AstraZeneca Pharmaceutical’s Nexium.Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is currently trading at Rs. 397.30, up by 3.70 points or 0.94% from its previous closing of Rs. 393.60 on the BSE.The scrip opened at Rs. 385.00 and has touched a high and low of Rs. 432.00 and Rs. 372.30 respectively. So far 96739 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 356.75 on 13-Mar-2020.Last one week high and low of the scrip stood at Rs. 432.00 and Rs. 363.85 respectively. The current market cap of the company is Rs. 30721.60 crore.The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.Hyderabad-based CSIR-Indian Institute of Chemical Technology (IICT) has partnered with Cipla to work on development of anti- viral drugs to contain COVID-19. Research on anti-viral drugs has been on throughout the world for long and many companies have developed molecules having anti-viral properties. But due to lack of demand, these molecules were not widely marketed. However, the CSIR-IICT decided to work on three such molecules -- remdesivir, favipiravir and baloxavir.Cipla urged the IICT director S Chandrasekhar to start work on these molecules on an immediate basis. Cipla would upscale the process on the basis of know-how given by CSIR-IICT.Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is currently trading at Rs. 405.00, up by 2.70 points or 0.67% from its previous closing of Rs. 401.75 on the BSE.The scrip opened at Rs. 407.55 and has touched a high and low of Rs. 411.00 and Rs. 401.00 respectively. So far 36948 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 356.75 on 13-Mar-2020.Last one week high and low of the scrip stood at Rs. 434.30 and Rs. 356.75 respectively. The current market cap of the company is Rs. 32511.44 crore.The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.Hyderabad-based CSIR-Indian Institute of Chemical Technology (IICT) has partnered with Cipla to work on development of anti- viral drugs to contain COVID-19. Research on anti-viral drugs has been on throughout the world for long and many companies have developed molecules having anti-viral properties. But due to lack of demand, these molecules were not widely marketed. However, the CSIR-IICT decided to work on three such molecules -- remdesivir, favipiravir and baloxavir. Cipla urged the IICT director S Chandrasekhar to start work on these molecules on an immediate basis. Cipla would upscale the process on the basis of know-how given by CSIR-IICT.Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is currently trading at Rs. 445.85, up by 1.00 points or 0.22% from its previous closing of Rs. 444.85 on the BSE.The scrip opened at Rs. 446.25 and has touched a high and low of Rs. 448.80 and Rs. 443.50 respectively. So far 14011 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 389.55 on 11-Oct-2019.Last one week high and low of the scrip stood at Rs. 462.85 and Rs. 435.60 respectively. The current market cap of the company is Rs. 35966.07 crore.The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.Cipla`s wholly-owned subsidiary -- Cipla Medpro South Africa has concluded an exclusive agreement securing originator and authorised generic brands of an atypical anti-psychotic drug, Quetiapine.The agreement involves AstraZeneca Pharmaceuticals, the originator of the Medicine, and Luye Pharma Hong Kong, which acquired the assets and rights to the medicine in select territories. The transaction allows Cipla Medpro to market and distribute the Medicine in South Africa and neighbouring countries.The existing portfolio consists of the originator brand Seroquel and the authorised generic brand Truvalin, medication which is used to treat mental health conditions such as schizophrenia, bipolar disorder, and major depressive disorder.Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.

Cipla is currently trading at Rs. 447.70, up by 4.55 points or 1.03% from its previous closing of Rs. 443.15 on the BSE.The scrip opened at Rs. 445.00 and has touched a high and low of Rs. 450.80 and Rs. 444.40 respectively. So far 17049 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 389.55 on 11-Oct-2019.Last one week high and low of the scrip stood at Rs. 462.85 and Rs. 435.60 respectively. The current market cap of the company is Rs. 35728.23 crore.The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.Cipla has acquired nutrition products’ portfolio from Wanbury. The company has acquired 4 brands-CPink, CDense, Productiv and Folinine to further strengthen its presence in women’s health.The nutraceutical products, to be sold under the 4 umbrella brands, would address various health needs for conditions arising due to nutritional deficiencies or insufficiencies. This includes supplements such as multivitamins, multimineral and antioxidants for adolescent girls, pregnant and lactating women, women going through menopause and for male and female reproductive health.Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is currently trading at Rs. 442.20, up by 2.50 points or 0.57% from its previous closing of Rs. 439.70 on the BSE.The scrip opened at Rs. 438.50 and has touched a high and low of Rs. 444.60 and Rs. 437.65 respectively. So far 53365 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 389.55 on 11-Oct-2019.Last one week high and low of the scrip stood at Rs. 462.85 and Rs. 435.60 respectively. The current market cap of the company is Rs. 35647.61 crore.The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.Cipla has reported a fall of 4.44% in its net profit at Rs 282.22 crore for the quarter ended December 31, 2019 as compared to Rs 295.32 crore for the same quarter in the previous year. However, total income of the company increased by 3% at Rs 2,999.48 crore for Q3FY20 as compared Rs 2,912.15 crore for the corresponding quarter previous year.On the consolidated basis, the company has reported a rise of 5.67% in its net profit attributed to the equity holders at Rs 351.03 crore for the quarter under review as compared to Rs 332.20 crore for the same quarter in the previous year. Total income of the company increased by 8.74% at Rs 4,443.13 crore for Q3FY20 as compared Rs 4,086.07 crore for the corresponding quarter previous year.

The company`s total revenue for the quarter ended December 2019 saw a slight change in the total revenue, having registered a total revenue of Rs. 29262.00 millions.A slender decline of -4.44% was recorded to Rs. 2822.20  millions from Rs. 2953.20 millions in the corresponding previous quarter.A decline of 5102.20 millions was observed in the OP in the quarter ended December 2019 from 5630.30 millions on QoQ basis. (Rs. in Million) Quarter ended Year to Date Year ended 201912 201812 % Var 201912 201812 % Var 201903 201803 % Var Sales 29262.00 28352.00 3.21 95257.10 89174.80 6.82 123740.10 114448.10 8.12 Other Income 732.80 769.50 -4.77 4794.40 4831.30 -0.76 5775.20 3348.80 72.46 PBIDT 5102.20 5630.30 -9.38 27219.30 20979.50 29.74 30795.20 25304.30 21.70 Interest 95.50 29.40 224.83 268.10 129.80 106.55 169.70 119.00 42.61 PBDT 5006.70 5600.90 -10.61 26951.20 20849.70 29.26 30625.50 24410.10 25.46 Depreciation 1431.40 1485.80 -3.66 4393.60 4251.00 3.35 5697.20 5296.10 7.57 PBT 3575.30 4115.10 -13.12 22557.60 16598.70 35.90 24928.30 19114.00 30.42 TAX 753.10 1161.90 -35.18 5421.60 4055.30 33.69 6044.20 4428.80 36.47 Deferred Tax 142.10 86.10 65.04 797.60 535.30 49.00 279.90 115.50 142.34 PAT 2822.20 2953.20 -4.44 17136.00 12543.40 36.61 18884.10 14685.20 28.59 Equity 1612.50 1611.30 0.07 1612.50 1611.30 0.07 1611.40 1610.20 0.07 PBIDTM(%) 17.44 19.86 -12.20 28.57 23.53 21.46 24.89 22.11 12.56

Cipla is currently trading at Rs. 466.90, up by 2.25 points or 0.48% from its previous closing of Rs. 464.65 on the BSE.The scrip opened at Rs. 466.00 and has touched a high and low of Rs. 467.45 and Rs. 459.45 respectively. So far 37738 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 389.55 on 11-Oct-2019.Last one week high and low of the scrip stood at Rs. 480.00 and Rs. 454.90 respectively. The current market cap of the company is Rs. 37675.02 crore.The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.Cipla has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA), indicating closure of the inspection at the Invagen (US) manufacturing facility. The agency had conducted inspection from December 2, 2019 to December 6, 2019. Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is currently trading at Rs. 460.20, up by 2.10 points or 0.46% from its previous closing of Rs. 458.10 on the BSE.The scrip opened at Rs. 458.00 and has touched a high and low of Rs. 461.40 and Rs. 454.90 respectively. So far 32105 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 389.55 on 11-Oct-2019.Last one week high and low of the scrip stood at Rs. 483.40 and Rs. 454.90 respectively. The current market cap of the company is Rs. 37110.66 crore.The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.United States Food and Drug Administration (USFDA) has concluded a cGMP inspection at Cipla’s API manufacturing facility in Bommasandra, Bangalore from January 20 - 24, 2020. The inspection ended with 4 observations which were procedural in nature and none of which were repeat or related to data integrity.Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla is currently trading at Rs. 462.65, up by 4.05 points or 0.88% from its previous closing of Rs. 458.60 on the BSE.The scrip opened at Rs. 463.70 and has touched a high and low of Rs. 466.00 and Rs. 460.55 respectively. So far 17250 shares were traded on the counter.The BSE group `A` stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 389.55 on 11-Oct-2019.Last one week high and low of the scrip stood at Rs. 466.00 and Rs. 446.85 respectively. The current market cap of the company is Rs. 37304.15 crore.The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.79% and 21.53% respectively.Cipla has acquired the brand name and trademark rights for Vysov & Vysov M (Vildagliptin plus Metformin) of the anti-diabetic drug, Vildagliptin for the Indian market. The company has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov & Vysov M and has witnessed a strong uptake for the product in India for the last couple of years. It is currently available across the country. The current market size of Vildagliptin is Rs 818 crore as per IQVIA MAT Nov 2019 in India.Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.